Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,812JPY
29 May 2015
Change (% chg)

¥-8 (-0.44%)
Prev Close
¥1,820
Open
¥1,820
Day's High
¥1,826
Day's Low
¥1,806
Volume
10,264,000
Avg. Vol
7,837,962
52-wk High
¥2,047
52-wk Low
¥1,273

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.53
Market Cap(Mil.): ¥4,112,878.00
Shares Outstanding(Mil.): 2,259.82
Dividend: 16.00
Yield (%): 1.65

Financials

  4503.T Industry Sector
P/E (TTM): 29.65 36.11 38.09
EPS (TTM): 61.38 -- --
ROI: 10.12 16.12 15.45
ROE: 10.51 16.91 16.49
Search Stocks

US FDA approves Astellas drug for invasive fungal infections

- U.S. health regulators on Friday approved Japanese drugmaker Astellas Pharma Inc's drug for the treatment of two rare, often fatal invasive fungal infections that target patients with blood cancers.

06 Mar 2015

UPDATE 1-US FDA approves Astellas drug for invasive fungal infections

March 6 - U.S. health regulators on Friday approved Japanese drugmaker Astellas Pharma Inc's drug for the treatment of two rare, often fatal invasive fungal infections that target patients with blood cancers.

06 Mar 2015

REFILE-TABLE-Astellas -9-MTH group results (IFRS)

(Operating forecast is core operating forecast, EPS forecast is core EPS forecast.) Feb 2 - Astellas Pharma Inc. CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Dec 31, 2014 Dec 31, 2013 Mar 31, 2015 LATEST YEAR-AGO COMPANY RESULTS RESULT FOREC

02 Feb 2015

FDA panel backs Astellas drug for invasive fungal infections

- A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can target patients with blood cancers.

22 Jan 2015

UPDATE 1-FDA panel backs Astellas drug for invasive fungal infections

Jan 22 - A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can target patients with blood cancers.

22 Jan 2015

BRIEF-Astellas announces end of license agreement with Janssen Biotech

* Announces end of license agreement with janssen biotech to develop oral janus kinase inhibitor

02 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: MarketLine (a Datamonitor Company)
£114.00
Provider: GlobalData
£81.00
Provider: Reuters Investment Profile
£10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks